Get the Stockscreener App
6.13
0.82%
0.05
Pre-market:
6.20
0.07
+1.14%
Aura Biosciences Inc stock is traded at $6.13, with a volume of 174.07K.
It is up +0.82% in the last 24 hours and down -0.81% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.08
Open:
$6.06
24h Volume:
174.07K
Relative Volume:
0.73
Market Cap:
$380.79M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.1927
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
+4.61%
1M Performance:
-0.81%
6M Performance:
+5.15%
1Y Performance:
-41.28%
1-Day Range:
$5.97
$6.20
1-Week Range:
$5.87
$6.595
52-Week Range:
$4.345
$11.29
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.13 | 377.69M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
How Aura Biosciences Inc. stock performs after earningsMarket Risk Report & Daily Growth Stock Tips - newser.com
How analysts rate Aura Biosciences Inc. stock todayRate Cut & Low Risk Growth Stock Ideas - newser.com
Can you recover from losses in Aura Biosciences Inc.July 2025 Spike Watch & Safe Entry Point Identification - newser.com
Applying big data sentiment scoring on Aura Biosciences Inc.Market Risk Report & Reliable Entry Point Trade Alerts - newser.com
How Aura Biosciences Inc. stock performs in weak economyWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
Should you hold or exit Aura Biosciences Inc. nowJuly 2025 Trends & Low Risk Growth Stock Ideas - newser.com
Is Aura Biosciences Inc. stock cheap compared to fundamentalsEarnings Recap Summary & Proven Capital Preservation Methods - newser.com
How to build a dashboard for Aura Biosciences Inc. stockOptions Play & Long-Term Investment Growth Plans - newser.com
Real time pattern detection on Aura Biosciences Inc. stockGDP Growth & Consistent Profit Trade Alerts - newser.com
Aura Biosciences Inc. stock outlook for YEAR2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Aura Biosciences CEO Makes Significant Stock Sale! - TipRanks
Aura Biosciences Director Elisabet de los Pinos Sells Shares to Cover Tax Obligations - TradingView
Form 4: AURA officer automatic sale of 896 shares to cover taxes - Stock Titan
AURA insider sale: 9,049 shares at $6.35 for RSU withholding - Stock Titan
Aura Biosciences’ Phase 3 Trial: A Potential Game-Changer in Ocular Melanoma Treatment - TipRanks
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Is Aura Biosciences Inc. stock trading near support levelsEarnings Trend Report & Safe Swing Trade Setups - Fundação Cultural do Pará
Aura Biosciences Advances Bladder Cancer Treatment with AU-011 Study - TipRanks
Aura Biosciences Advances Eye Cancer Treatment with Phase 2 Trial Update - TipRanks
Published on: 2025-10-27 06:14:42 - newser.com
Published on: 2025-10-27 03:33:03 - newser.com
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):